The situation has not been the same with pioglitazone.
这种情况与吡格列酮不同。
Pioglitazone clearly has fallen on the side of cardiovascular benefits or very close.
吡格列酮明显倾向于心血管获益方面或者非常接近。
We did not observe similar associations in a secondary analysis evaluating pioglitazone.
我们在第二次罗格列酮分析评估中没有看到类似的相关性。
We did not observe similar associations in a secondary analysis evaluating pioglitazone.
我们在第二次罗格列酮分析评估中没有看到类似的相关性。
应用推荐